Abstract 471TiP
Background
Neurokinin-1 (NK-1) receptor antagonists will prevent CINV effectively but are not affordable for patients of low socioeconomic status and there is still an unmet need for the prevention of CINV in the low socio-economic setting. Recent studies show olanzapine which blocks multiple neurotransmitters in the brain is also effective in preventing CINV and pregabalin which inhibits the release of neurotransmitters is effective in preventing postoperative nausea and vomiting. A mechanistic synergism is expected between the olanzapine and pregabalin combination. Therefore, this trial was designed to evaluate the add-on combination of olanzapine and pregabalin in the management of CINV.
Trial design
This trial is a group sequential response adaptive randomized double-blinded clinical trial. The O'Brien-Fleming boundaries were defined for efficacy and futility. The total sample size to achieve the primary objective of the difference in the proportion of patients with “overall no nausea” was calculated to be 84, with an allocation ratio of 1:1. Depending on the results of each interim analysis, the allocation ratio will be changed, and more patients will be allocated to the well-performing arm. In our study, we enrolled cancer patients belonging to low socio-economic status who planned to receive highly emetogenic cancer chemotherapeutic agents and the standard of care antiemetic premedication (ondansetron 8mg and dexamethasone 8mg). Patients received either olanzapine 5 mg plus pregabalin 75 mg orally or a matching placebo daily on day 1 through day 5 in addition to their standard antiemetic premeditations. In stage one of the trial, 30 patients were equally randomized into two groups and the interim analysis showed the experimental group performed better in terms of “overall no nausea” (40% vs. 6.6 % p value-0.042). However, it didn't breach the boundary (0.0035) fixed by the O'Brien and Fleming approach. So, the trial is being continued to the second stage. As the Z (1.73) value was between 1.5-2, the allocation ratio has been changed to 2:1 for the next stage of the trial as per the protocol.
Clinical trial identification
CTRI/2021/08/035451.
Legal entity responsible for the study
The authors.
Funding
Indian Council of Medical Research (ICMR), India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract